Alumis (ALMS) Other Non-Current Liabilities (2023 - 2025)
Alumis (ALMS) reported Other Non-Current Liabilities of $123000.0 for Q4 2025, down 84.87% year-over-year from $813000.0 in Q4 2024, and down 27.22% quarter-over-quarter from $169000.0 in Q3 2025.
Alumis (ALMS) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends
Alumis (ALMS) has 3 years of Other Non-Current Liabilities data on file, last reported at $123000.0 in Q4 2025.
- Other Non-Current Liabilities for Q4 2025 came in at $123000.0, down 84.87% year-over-year; the trailing twelve-month figure through Dec 2025 was $123000.0 (down 84.87% YoY), and the FY2025 annual result was $123000.0, down 84.87% from the prior year.
- Other Non-Current Liabilities declined to $123000.0 in Q4 2025 per ALMS's latest filing, from $169000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.8 million in Q4 2023 and troughed at $123000.0 in Q4 2025.
- A 3-year average of $763500.0 and a median of $700500.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities sank 54.09% in 2024, then tumbled 84.87% in 2025.
- A 3-year view of Other Non-Current Liabilities shows it stood at $1.8 million in 2023, then slumped by 54.09% to $813000.0 in 2024, then plunged by 84.87% to $123000.0 in 2025.
- Business Quant data shows ALMS's Other Non-Current Liabilities at $123000.0 in Q4 2025, $169000.0 in Q3 2025, and $386000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | 169,000.00 |
| Jun 30, 2025 | 386,000.00 |
| Mar 31, 2025 | 588,000.00 |
| Dec 31, 2024 | 813,000.00 |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Dec 31, 2023 | 1.77 Mn |